VIPoma other imaging findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Other imaging studies for VIPoma include [[somatostatin]] receptor scintigraphy and PET scan. | Other imaging studies for VIPoma include [[somatostatin]] receptor scintigraphy and PET scan. | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
[[Somatostatin]] receptor [[scintigraphy]] is used to localise the [[tumor]], which is usually [[metastasis|metastatic]] at presentation. | [[Somatostatin]] receptor [[scintigraphy]] is used to localise the [[tumor]], which is usually [[metastasis|metastatic]] at presentation. |
Revision as of 20:58, 27 October 2015
VIPoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
VIPoma other imaging findings On the Web |
American Roentgen Ray Society Images of VIPoma other imaging findings |
Risk calculators and risk factors for VIPoma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Other imaging studies for VIPoma include somatostatin receptor scintigraphy and PET scan.
Other Imaging Findings
Somatostatin receptor scintigraphy is used to localise the tumor, which is usually metastatic at presentation.
-
PET-CT with MBq 68-Gallium-DOTATOC showing enhancement of multiple lesions in the right lobe of the liver (upper image) and a slight enhancement in the caudal pancreas (lower image).[1]
References
- ↑ Müller, Sven; Kupka, Susan; Königsrainer, Ingmar; Northoff, Hinnak; Sotlar, Karl; Bock, Thomas; Kandolf, Reinhard; Traub, Frank; Königsrainer, Alfred; Zieker, Derek (2012). "MSH2 and CXCR4 involvement in malignant VIPoma". World Journal of Surgical Oncology. 10 (1): 264. doi:10.1186/1477-7819-10-264. ISSN 1477-7819.